vs
Essent Group Ltd.（ESNT）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是Essent Group Ltd.的2.0倍（$622.0M vs $312.4M），Essent Group Ltd.净利率更高（49.6% vs 34.4%，领先15.2%），Royalty Pharma plc同比增速更快（4.8% vs -0.8%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs 2.3%）
Essentra PLC是一家面向全球市场的塑料及纤维产品供应商，总部位于英国牛津郡基德灵顿，业务网络覆盖全球多个区域，目前在伦敦证券交易所上市，可面向各行业客户提供多元化的相关产品及配套服务，在所属细分领域拥有较高的市场认可度。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
ESNT vs RPRX — 直观对比
营收规模更大
RPRX
是对方的2.0倍
$312.4M
营收增速更快
RPRX
高出5.6%
-0.8%
净利率更高
ESNT
高出15.2%
34.4%
两年增速更快
RPRX
近两年复合增速
2.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $312.4M | $622.0M |
| 净利润 | $155.0M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | 59.1% | 62.4% |
| 净利率 | 49.6% | 34.4% |
| 营收同比 | -0.8% | 4.8% |
| 净利润同比 | -7.7% | 2.9% |
| 每股收益（稀释后） | $1.61 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESNTRPRX
| Q4 25 | $312.4M | $622.0M | ||
| Q3 25 | $311.8M | $609.3M | ||
| Q2 25 | $319.1M | $578.7M | ||
| Q1 25 | $317.6M | $568.2M | ||
| Q4 24 | $315.0M | $593.6M | ||
| Q3 24 | $316.6M | $564.7M | ||
| Q2 24 | $312.9M | $537.3M | ||
| Q1 24 | $298.4M | $568.0M |
净利润ESNTRPRX
| Q4 25 | $155.0M | $214.2M | ||
| Q3 25 | $164.2M | $288.2M | ||
| Q2 25 | $195.3M | $30.2M | ||
| Q1 25 | $175.4M | $238.3M | ||
| Q4 24 | $167.9M | $208.2M | ||
| Q3 24 | $176.2M | $544.0M | ||
| Q2 24 | $203.6M | $102.0M | ||
| Q1 24 | $181.7M | $4.8M |
营业利润率ESNTRPRX
| Q4 25 | 59.1% | 62.4% | ||
| Q3 25 | 63.9% | 70.1% | ||
| Q2 25 | 72.4% | 36.3% | ||
| Q1 25 | 65.2% | 94.0% | ||
| Q4 24 | 61.9% | 60.9% | ||
| Q3 24 | 65.6% | — | ||
| Q2 24 | 76.4% | 50.2% | ||
| Q1 24 | 71.6% | -13.0% |
净利率ESNTRPRX
| Q4 25 | 49.6% | 34.4% | ||
| Q3 25 | 52.7% | 47.3% | ||
| Q2 25 | 61.2% | 5.2% | ||
| Q1 25 | 55.2% | 41.9% | ||
| Q4 24 | 53.3% | 35.1% | ||
| Q3 24 | 55.6% | 96.3% | ||
| Q2 24 | 65.1% | 19.0% | ||
| Q1 24 | 60.9% | 0.8% |
每股收益（稀释后）ESNTRPRX
| Q4 25 | $1.61 | $0.49 | ||
| Q3 25 | $1.67 | $0.67 | ||
| Q2 25 | $1.93 | $0.07 | ||
| Q1 25 | $1.69 | $0.55 | ||
| Q4 24 | $1.59 | $0.46 | ||
| Q3 24 | $1.65 | $1.21 | ||
| Q2 24 | $1.91 | $0.23 | ||
| Q1 24 | $1.70 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $5.8B | $9.7B |
| 总资产 | $7.4B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资ESNTRPRX
| Q4 25 | — | $618.7M | ||
| Q3 25 | — | $938.9M | ||
| Q2 25 | — | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $929.0M | ||
| Q3 24 | — | $950.1M | ||
| Q2 24 | — | $1.8B | ||
| Q1 24 | — | $843.0M |
总债务ESNTRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益ESNTRPRX
| Q4 25 | $5.8B | $9.7B | ||
| Q3 25 | $5.7B | $9.6B | ||
| Q2 25 | $5.7B | $9.5B | ||
| Q1 25 | $5.7B | $9.8B | ||
| Q4 24 | $5.6B | $10.3B | ||
| Q3 24 | $5.6B | $10.3B | ||
| Q2 24 | $5.4B | $9.8B | ||
| Q1 24 | $5.2B | $9.9B |
总资产ESNTRPRX
| Q4 25 | $7.4B | $19.6B | ||
| Q3 25 | $7.4B | $19.3B | ||
| Q2 25 | $7.2B | $18.3B | ||
| Q1 25 | $7.2B | $17.6B | ||
| Q4 24 | $7.1B | $18.2B | ||
| Q3 24 | $7.1B | $18.0B | ||
| Q2 24 | $6.7B | $17.7B | ||
| Q1 24 | $6.6B | $16.1B |
负债/权益比ESNTRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $856.1M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $848.7M | — |
| 自由现金流率自由现金流/营收 | 271.7% | — |
| 资本支出强度资本支出/营收 | 2.4% | — |
| 现金转化率经营现金流/净利润 | 5.52× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $1.5B | — |
8季度趋势，按日历期对齐
经营现金流ESNTRPRX
| Q4 25 | $856.1M | $827.1M | ||
| Q3 25 | $215.9M | $702.6M | ||
| Q2 25 | $189.5M | $364.0M | ||
| Q1 25 | $221.6M | $596.1M | ||
| Q4 24 | $861.5M | $742.5M | ||
| Q3 24 | $229.2M | $703.6M | ||
| Q2 24 | $188.7M | $658.2M | ||
| Q1 24 | $216.9M | $664.6M |
自由现金流ESNTRPRX
| Q4 25 | $848.7M | — | ||
| Q3 25 | $210.6M | — | ||
| Q2 25 | $188.8M | — | ||
| Q1 25 | $221.3M | — | ||
| Q4 24 | $854.8M | — | ||
| Q3 24 | $228.7M | — | ||
| Q2 24 | $187.6M | — | ||
| Q1 24 | $212.5M | — |
自由现金流率ESNTRPRX
| Q4 25 | 271.7% | — | ||
| Q3 25 | 67.5% | — | ||
| Q2 25 | 59.2% | — | ||
| Q1 25 | 69.7% | — | ||
| Q4 24 | 271.3% | — | ||
| Q3 24 | 72.2% | — | ||
| Q2 24 | 60.0% | — | ||
| Q1 24 | 71.2% | — |
资本支出强度ESNTRPRX
| Q4 25 | 2.4% | — | ||
| Q3 25 | 1.7% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 2.1% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 0.3% | — | ||
| Q1 24 | 1.5% | — |
现金转化率ESNTRPRX
| Q4 25 | 5.52× | 3.86× | ||
| Q3 25 | 1.31× | 2.44× | ||
| Q2 25 | 0.97× | 12.06× | ||
| Q1 25 | 1.26× | 2.50× | ||
| Q4 24 | 5.13× | 3.57× | ||
| Q3 24 | 1.30× | 1.29× | ||
| Q2 24 | 0.93× | 6.45× | ||
| Q1 24 | 1.19× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESNT
| Mortgage Insurance Segment | $192.4M | 62% |
| Other | $120.0M | 38% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
